Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.50 |
| ▸ | SCN1A | P35498 | 5/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184154 | 1.00 | SCN8A (0.50) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL10067652 | 0.94 | SCN9A (0.48) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL1603705 | 0.92 | SCN9A (0.49) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL1603703 | 0.92 | SCN9A (0.49) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL2626281 | 0.90 | KMT2A (0.52) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL2625943 | 0.88 | KMT2A (0.47) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL2626538 | 0.88 | SCN9A (0.49) | SCN8ASCN1ASCN9AKMT2ASCN5A | |
| SCHEMBL184272 | 0.86 | SCN9A (0.47) | SCN9AKMT2ASCN5ACYP2C9 | |
| SCHEMBL184273 | 0.86 | SCN9A (0.47) | SCN9AKMT2ASCN5ACYP2C9 | |
| SCHEMBL2625908 | 0.86 | KMT2A (0.55) | SCN8ASCN1ASCN9AKMT2ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097636-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097636-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097636-B2 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2220080-B1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2220080-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064752-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064752-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124655-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | SCN8A 99/4885SCN1A 65/4885SCN9A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.